Analysis of American medical records has shown that a treatment taken daily by people who have had organ transplants to prevent organ rejection may also protect against Alzheimer’s disease.
This result was published in the recent edition of the Journal of Alzheimer’s Disease from researchers at the University of Texas Medical Branch, USA. The research team analysed data from the medical records of 2,644 people who received organ transplants and as a result took daily ‘calcineurin inhibitor-based medications.’
When you read something that says ‘metal–oxide valence-change memristive devices’ it may sound like something from a sci-fi movie but in fact it is a device that Australian based researchers have used to mimic the way the human brain processes information.
Over the past year, a few high profile Alzheimer’s disease human clinical trials have been studying the effectiveness of ‘anti-amyloid therapies’. These therapies are designed to bind to, and remove amyloid plaques in the brain, one of the major pathological markers of Alzheimer ’s disease.
In theory, these therapies sound simple and should be effective but in reality it is proving much more difficult than first thought. So far, the results from human clinical trials have not shown what many people were hoping.
The Queensland Brain Institute, University of Queensland last week hosted the 9th Alzheimer’s + Parkinson’s Disease (A+PD) Symposium. The two day program was organised by two of Australia’s leading biomedical dementia researchers Professor Jurgen Gotz (from UQ) and Professor Lars Ittner (from UNSW).
Edaravone, a treatment which is currently used overseas for people who have had a stroke, has been shown to be effective in reducing key Alzheimer’s disease toxic markers and improving cognition in mice.
An experimental Alzheimer’s disease treatment called Aducanumab trialled in people with early stages of Alzheimer’s disease has shown to reduce amyloid plaque levels, and in turn slow down their cognitive decline.
These interim results were recently presented by Pharmaceutical Company Biogen Idec at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France. This Phase 1b clinical trial included 166 people with the early stages of Alzheimer’s disease.
New Australian research has provided more evidence towards an interesting approach for treating Alzheimer’s disease. Results suggest that infrared light can remove and reduce the levels of toxic proteins and plaques associated with the disease, in the brains of mice.
Anavex 2-73 has been found to prevent and reduce two critical hallmarks of Alzheimer’s disease – mitochondrial dysfunction and oxidative stress – in a mouse model of Alzheimer's disease.
In this new animal trial, recently published in the Journal Frontiers in Cellular Neuroscience, researchers found that after they injected male mice (genetically modified to develop Alzheimer’s disease) with the Anavex 2-73 treatment, they were able to preserve mitochondrial functionality and enhance neuroprotective activity.